Printer Friendly

JON SAXE AND DR. FRED CRAVES JOIN INCYTE'S BOARD OF DIRECTORS

 PALO ALTO, Calif., Aug. 23 /PRNewswire/ -- Incyte Pharmaceuticals Inc., today announced the appointment of Jon Saxe and Frederick Craves, Ph.D., to its board of directors.
 Saxe, currently president of Saxe Associates Inc., served as president and chief executive officer of Synergen Inc. and vice president of Licensing and Corporate Development for Hoffmann-La Roche. Saxe is also a director of InSite Vision Inc. and Protein Design Labs Inc.
 Dr. Craves, currently an independent management consultant, served as president and chief executive officer of Berlex Biosciences, a subsidiary of Schering AG, and was chairman, chief executive officer and president of Codon Corp. Craves is chairman of the board for NeoRx Corp. and Microprobe Corp.
 Incyte Pharmaceuticals is a privately held biotechnology company engaged in the large-scale sequencing of cDNAs from human cells and tissues. The company is using computer-aided analysis to correlate its growing database of new gene sequences with the biology of the disease process, with emphasis on the identification and development of protein biotherapeutic agents and targets.
 -0- 8/23/93
 /CONTACT: Roy A. Whitfield of Incyte Pharmaceuticals, 415-855-0555/


CO: Incyte Pharmaceuticals Inc. ST: California IN: MTC SU: PER

LM-JL -- SD002 -- 4939 08/23/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 23, 1993
Words:199
Previous Article:ASSET INVESTORS CORP. DECLARES SECOND QUARTER DIVIDEND OF TEN CENTS PER SHARE
Next Article:SENETEK GETS U.S. PATENT ON MALE SEXUAL DYSFUNCTION DRUG
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters